Lung Cancer is the most frequently diagnosed of all cancers and is responsible for approximately 1.38 million of deaths each year worldwide. Non-small-cell-cancer (NLCSC) is the most common form of cancer and first-line treatment of advanced NLCSC often involves combination chemotherapy.
However, for patients with advance NLCSC harbouring an activating mutation in the Tyrosine Kinase (TK) domain of the Epidermal Growth Factor Receptor (EGFR), targeted treatment is available in the form of the EGFR TK inhibitors (TKIs) like gefitinib and erlotinib.
One of the greatest advances in lung cancer treatment in recent years has been the user of medications that target epidermal growth factor mutations (EGFR mutations.) For people who test positive for this mutation, medications such as Tarceva (erlotinib) can extend survival and improve quality of life – all without the degree of side effects seen with other forms of chemotherapy.
• A real-time PCR test for the qualitative detection and identification of mutations in exons 18, 19, 20 and 21 of the Epidermal Growth Factor Receptor (EGFR) gene in DNA.
•Intended to be used to identify patients with advanced NSCLC whose tumors harbor mutations in exons 18, 19, 20 and 21 of the EGFR gene, and to select patients for treatment with small molecule Tyrosine Kinase inhibitors (TKIs) that target EGFR.
•Utilizes formalin-fixed paraffin-embedded (FFPET) human non-small cell lung cancer (NSCLC) tumor tissue.
•Detects 41 mutations in Exons 18, 19, 20 and 21 of the EGFR geneme.
•Can typically be obtained from a single 5um FFPET section with ~10% tumor.
•Ensures clinicians are provided accurate results to make therapy decisions.